Bayer AG

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

The Supreme Court has rejected Bayer's appeal to shut down thousands of lawsuits claiming that its Roundup weedkiller causes cancer.

Supreme Court rejects Bayer bid to stop Roundup lawsuits

The U.S. Supreme Court on Tuesday rejected Bayer AG's bid to dismiss legal claims by customers who contend its Roundup weedkiller causes cancer as the German company seeks to avoid potentially billions of dollars in damages.

U.S. Supreme Court rejects Bayer bid to nix Roundup weedkiller suits

A U.S. jury found Bayer's Roundup weedkiller did not cause an Oregon man's cancer, the German agriculture and pharmaceuticals company said on Saturday, handing the firm its fourth consecutive trial victory over such claims.

Bayer wins fourth Roundup weedkiller case in U.S

The U.S. Supreme Court on Monday took no action on Bayer AG's bid to dismiss legal claims by customers who contend its Roundup weedkiller causes cancer as the German company seeks to avoid potentially billions of dollars in damages.

U.S. Supreme Court takes no action on Bayer bid to nix weedkiller suits

The U.S. Supreme Court could announce as soon as Monday whether it will hear Bayer's bid to dismiss claims its Roundup weedkiller causes cancer as the company seeks to avoid potentially billions of dollars more in damages and payouts.

U.S. Supreme Court will soon decide whether to hear Bayer's weedkiller case

LEVERKUSEN, Germany & SAN DIEGO--(BUSINESS WIRE)--Bayer AG and its wholly owned San Diego-based subsidiary Vividion Therapeutics, Inc. (Vividion) will highlight how the two companies have fostered innovation and collaboration through Bayer's “arm's length” operating model during a presentation at the 2022 BIO International Convention. Bayer has built a strong partnership with Vividion since its acquisition of the biopharmaceutical company in 2021, deploying an innovative business model that all

Bayer's Vividion Emerging as Significant Player in San Diego Biotech Hub

Cisco Systems

Equinor

Intel

AT&T

Unilever

Volkswagen AG

These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. The post 7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend appeared first on InvestorPlace.

7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, one of the country's leading life-sciences companies, today announced two changes to its U.S. Country Leadership Team. Brian Branca has been appointed to the position of Bayer U.S. Chief Financial Officer (CFO), effective June 1, 2022. Branca has been with Bayer since 2006 and most recently served as Bayer U.S. Vice President and Treasurer. He has held numerous financial leadership roles throughout his tenure with the company, including serving as CFO for

Bayer Appoints Two New Members to U.S. Country Leadership Team

Grifols, S.A.

Takeda Pharmaceutical

These three healthcare stocks should hold their value for years.

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

Atara Biotherapeutics Inc (NASDAQ: ATRA) received notification that Bayer AG's (OTC: BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271,.

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022. These presentations continue to reinforce Bayer's position as an innovator in oncology and ongoing dedication to advancing oncology treatments for patients on a global scale. NUBEQA® (darolutamide) data presented will include overall survival (OS) and prostate-specific antigen (PSA) results from the investigationa

Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care at 2022 ASCO Annual Meeting

Shares in Bayer AG fell in opening trade on Wednesday after a U.S. Justice department brief recommended that the Supreme Court reject a company appeal to review a case linking its Roundup weedkiller to a type of cancer.

Bayer shares plunge after U.S. Justice Department asks Supreme Court to reject Roundup appeal

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Oliver Maier - Head, IR Werner Baumann - CEO Wolfgang Nickl - CFO Rodrigo Santos - President, the Crop Science Division Stefan Oelrich - Head, the Pharmaceuticals Division Conference Call Participants Vincent Andrews - Morgan Stanley Pete Verdult - Citigroup Sachin Jain - Bank of America Michael Leuchten - UBS James Quigley - Morgan Stanley Keyur Parekh - Goldman Sachs Falko Friedrich - Deutsche Bank Christian Faitz - Kepler Cheuvreux Steve Byrne - Bank of America Richard Vosser - JPMorgan Operator Ladies and gentlemen, thank you for standing by. Welcome to Bayer's Investor and Analyst Conference Call on the First Quarter 2022 Results.

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q1 2022 Results - Earnings Call Transcript

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

Agriculture and pharmaceuticals company Bayer reported quarterly adjusted core earnings rose a better-than-expected 27.5% on strong gains at its seeds and pesticides business.

Bayer's farming business drives Q1 earnings beat

Shareholders of Bayer on Friday voted to reprimand the German drug and farming supplies maker for its top management pay scheme, after one leading proxy advisory group said it did not adequately reflect Bayer's litigation burden.

Bayer gets shareholder rebuke for management remuneration

German diversified group Bayer has seen a "very successful start to the year", driven by a favourable environment in agricultural markets, it said on Monday.

Bayer says start to the year very successful thanks to agriculture unit

Norway's $1.3 trillion wealth fund will cast a vote in support next week of top management at German drug and farm products maker Bayer AG, but will vote against the remuneration package of CEO Werner Baumann, it said on Sunday.

Norway's sovereign fund will vote to support Bayer management

Ginkgo Bioworks Holdings

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer's West Sacramento Biologics Research & Development (R&D) site and internal discovery and lead optimization platform. The contemplated transaction, projected to close before the end of 2022 pending final negotiation of the agreement terms and subject to regulatory approvals, would also bring Joyn Bio's nitrogen-fixing technologies to Bayer, success

Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms

AbbVie

Two health care companies most investors might not be familiar with were among the four biggest stock market gainers in the first quarter, according to an analysis by Evaluate.

AbbVie and Bayer Record Hefty Share Price Gains in 1st Quarter

Bayer's technical picture improved in the last few months, and the company also reported solid fiscal 2021 results.

Bayer: Still A Buy

Apple

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Apollo Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Preferred Apartment Communities

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bank of Montreal

The war in Ukraine continues to dominate market movements. I am not selling anything and predominantly focus on adding dividend income via select purchases.

My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from prespecified exploratory subgroup analyses of FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials. These analyses investigated KERENDIA® (finerenone) versus placebo on composite cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D), with and without a history of atherosclerotic cardiovascular disease (ASCVD).

Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular Disease

Deutsche Bank

The DAX index made a spectacular recovery in the first quarter in sync with other top indices. It rose by more than 16% from its lowest level this year even as risks to the German economy remained.

Here are the best DAX index constituents in Q1

LEVERKUSEN, Germany--(BUSINESS WIRE)--Today, Bayer held its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies. The event followed Bayer's recent short- and mid-term pipeline updates for its Pharma and Crop Science Divisions and shared further insights on Bayer's ongoing progress to drive long-term breakthrough innovations in the Life Sciences. Renowned experts and Bayer executives illustrated how a forthco

Bayer Set to Drive Breakthrough Innovations in the Life Sciences

News for Bayer AG Stock (BAYRY)